AZD7789: A phase 1/2 trial of AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma

This trial is testing AZD7789 in people with relapsed or refractory classical Hodgkin lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05216835

Trial aim and background

The aim of this trial is to find out the safety and efficacy of AZD7789 in adults with classical Hodgkin lymphoma that has either come back (relapsed) or not responded to previous treatment (refractory lymphoma).

This trial involves the participant having AZD7789 for a maximum of 35 cycles.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

People over 16 with classical Hodgkin Lymphoma which has failed to respond to two previous systemic treatments may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • Manchester
  • Oxford

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05216835 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.